First Treatment for Chronic Sialorrhea Tops SPT Week in Review

Article

Top news of the week from Specialty Pharmacy Times.

5. FDA Approves New Treatment Regimen for Schizophrenia

Officials with the FDA have approved Alkermes' aripiprazole lauroxil (Aristada Initio) extended-release product for the treatment of schizophrenia in adults. Read more.

4. Immunotherapy Combo Treatment Improves Progression-Free Survival in Triple-Negative Breast Cancer

Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer. Read more.

3. Prostate Cancer Genetic Test Can Provide Readout of Inherited Disease Risk

Using a DNA test to identify genetic variants in men that increase the likelihood of prostate cancer may help guide interventions for those at high risk and improve disease prevention. Read more.

2. Clinical Trial to Investigate Vaccine/Immunotherapy Combo Treatment for Metastatic Colorectal Cancer

An investigational anti-cancer vaccine will be paired with nivolumab to determine whether the combination therapy will improve survival in patients with the disease. Read more.

1. FDA OKs Treatment for Excessive Drooling in Adult Patients with Neurological Disorders

IncobotulinumtoxinA is the first and only neurotoxin approved for this indication in the United States. Read more.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.